The Infectious Disease Research Institute (IDRI) is a global leader in research dedicated to preventing, detecting, and treating disease. Recently, IDRI has developed several technologies which can synthesize the genetic material of viruses. These technologies enable medicine to reap the benefits of using viral material without the danger of healthy cells becoming infected by an actual virus. Each of these technologies been validated with extensive animal testing.
Among other applications, these technologies will allow for major advances in immunotherapy cancer treatment. IDRI, itself a non-profit, is spinning off these immunotherapy applications into a for-profit entity called OnCo in order to raise the $25 million necessary to complete the first phase of human trials.